Christopher Ogden

Royal Marsden NHS Foundation Trust, St Mary's Hospital

Papers

2

Total Citations

61

H-Index

2

About

Christopher Ogden is a pioneering urological surgeon whose research has fundamentally shaped the treatment of localised prostate cancer. His work centres on two key areas: advancing minimally invasive surgical techniques and rigorously comparing modern radiotherapy with surgery through landmark clinical trials. Ogden led the UK’s first clinical programme for robotically assisted laparoscopic radical prostatectomy, a major contribution documented in his highly cited 2006 paper (30 citations) that established a teamwork-based framework for adopting this complex technology. His most impactful work is the PACE-A trial (31 citations), an international phase 3 randomised controlled trial that directly compared stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer. This study addressed a critical therapeutic equipoise, providing the first randomised evidence on quality-of-life outcomes between these two standard treatments. By spearheading this trial and pioneering robotic surgery in the UK, Ogden has provided the urological community with essential comparative effectiveness data, helping guide shared decision-making for patients facing early-stage prostate cancer.

Research Focus

Key Achievements

2
H-Index
2
Papers
61
Total Citations
31
Avg Citations/Paper
🏆 Most Cited Paper
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
31 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 24
🏛 Institutions: Royal Marsden NHS Foundation Trust, St Mary's Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago